Avan J. Armaghani, MD, highlights exciting research in hormone receptor‒positive, HER2-negative breast cancer that will be presented at the San Antonio Breast Cancer Symposium 2024. In early-stage settings, new neoadjuvant strategies are being explored, including a phase 2 trial of a HER3-directed antibody-drug conjugate aimed at improving response rates.
In metastatic cases, the EMBER-3 trial will present findings on the oral SERD (selective estrogen receptor degrader) imlunestrant with or without abemaciclib, while the PADMA study examines first-line treatments in high-risk patients, comparing endocrine therapy plus palbociclib against chemotherapy. Dr Armaghani is also interested in the BWEL trial's focus on weight loss interventions for patients with breast cancer.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2024: Previewing New Data in HR+/HER2- Breast Cancer - Medscape - Nov 26, 2024.
Comments